Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
March 27 2023 - 7:30AM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that John Evans, chief executive officer, will
participate in a fireside chat during the Guggenheim 2023 Genomic
Medicines and Rare Disease Day on Monday, April 3, 2023 at 10:10
a.m. ET in NYC.
A live webcast will be available in the investor section of the
company's website at www.beamtx.com, and will be archived for 60
days following the presentation.
About Beam TherapeuticsBeam Therapeutics
(Nasdaq: BEAM) is a biotechnology company committed to establishing
the leading, fully integrated platform for precision genetic
medicines. To achieve this vision, Beam has assembled a platform
that includes a suite of gene editing and delivery technologies and
is in the process of building internal manufacturing capabilities.
Beam’s suite of gene editing technologies is anchored by base
editing, a proprietary technology that is designed to enable
precise, predictable and efficient single base changes, at targeted
genomic sequences, without making double-stranded breaks in the
DNA. This has the potential to enable a wide range of potential
therapeutic editing strategies that Beam is using to advance a
diversified portfolio of base editing programs. Beam is a
values-driven organization committed to its people, cutting-edge
science, and a vision of providing life-long cures to patients
suffering from serious diseases.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Sep 2023 to Sep 2024